Family Caregiver Experiences in the Inpatient and Outpatient Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation Settings: A Qualitative Study

Many patients with high-risk hematologic malignancies and other illnesses that result in bone marrow failure syndromes undergo allogeneic hematopoietic cell transplantation (allo-HCT).1 –3 A potentially curative therapy, HCT often involves a protracted treatment course traditionally delivered in the inpatient setting where patients experience an intense 3–4-week hospitalization with substantial toxicities resulting from the early transplant process.4–6 Several factors such as increased options for round-the-clock staff availability provides opportunity to relieve caregiver burden, ongoing close post-HCT follow-up care with the medical team, potentially higher patient quality of life in the home environment, reduced exposure to nosocomial infections, and cost containment , have led to more allo-HCTs being offered in outpatient settings (outpatient HCT) as an acceptable alternative to inpatient HCT.

Source: Biology of Blood and Marrow Transplantation - September 29, 2023 Category: Hematology Authors: Tamryn F. Gray, Khuyen M. Do, Hermioni L. Amonoo, Lauren Sullivan, Amar Kelkar, William Pirl, Marilyn Hammer, James A. Tulsky, Areej El-Jawahri, Corey Cutler, Ann H. Partridge Source Type: research